Revenue and Financial Performance - Revenues for Q3 2024 were $14 thousand, a decrease from $29 thousand in Q3 2023[3] - Total revenues for September 2024 were $14 million, a decrease from $29 million in September 2023[22] Operating Expenses - Operating expenses for Q3 2024 increased to $5.3 million from $1.5 million in Q3 2023[3] - General and administrative expenses for Q3 2024 increased to $2.9 million from $0.9 million in Q3 2023[5] - Net loss from operations was $(5.312) million in September 2024, compared to $(1.463) million in September 2023[22] Research and Development - Research and development expenses for Q3 2024 rose to $2.4 million, up from $0.6 million in Q3 2023[4] - Research and development expenses increased to $2.415 million in September 2024 from $603 thousand in September 2023[22] Net Income and Loss - Net income for Q3 2024 was $1.4 million, compared to $1.8 million in Q3 2023[7] - Change in fair value of warrants contributed $6.669 million to other income in September 2024, up from $596 thousand in September 2023[22] Cash and Liquidity - Cash, cash equivalents, and restricted cash totaled $3.2 million as of September 30, 2024[8] - The company anticipates insufficient cash to meet operating needs for the next 12 months, raising substantial doubt about its ability to continue as a going concern[9] - Net cash used in operating activities was $(12.548) million for the period ending September 2024, compared to $(2.597) million in the same period of 2023[23] - Cash, cash equivalents, and restricted cash decreased by $4.384 million to $3.235 million at the end of September 2024[23] Financing Activities - Proceeds from the exercise of Post-Merger Warrants by Juvenescence amounted to $4.988 million in September 2024[23] - Net cash provided by financing activities was $8.181 million in September 2024, down from $10.080 million in September 2023[23] - Issuance of common stock upon conversion of Preferred Stock totaled $36.404 million in September 2024[23] - Merger and issuance of common stock upon consummation of Merger on March 26, 2024, amounted to $961 thousand[23] Assets and Liabilities - Total assets as of September 30, 2024, were $7.435 million, down from $8.968 million at the end of 2023[18] Product Development and Partnerships - SER-252, an investigational apomorphine therapy, is planned for clinical testing in 2025[10] - The POZ Platform™ technology has potential for broad applications, including a non-exclusive license agreement with Pfizer for LNP drug delivery formulations[12]

HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2024, along with key recent updates. Recent Highlights Partnership and Presentations with Enable Injections: Building on its collaboration wit ...

Table of Contents Title of each class Trading Symbol Name of exchange on which registered Common Stock, par value $0.0001 per share SER NYSE American UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ...

HUNTSVILLE, AL, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made grants of options to purchase an aggregate of 60,500 shares of Serina’s common stock to three new non-executive employees on November 6, 2024 (each, an “Option Grant”). Each Option Grant has ...

Exhibit 99.1 Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights HUNTSVILLE, August 9, 2024 (GLOBE NEWSWIRE) — Serina Therapeutics ("Serina") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today reported financial results for the quarter ended June 30, 2024 and provided business highlights. Recent Highlights ● Partnership with Enable Injections. The Company will develop and commerc ...

Financial Performance - Revenues for the three and six months ended June 30, 2024, were not material[204]. - The net loss attributable to Serina for the six months ended June 30, 2024, was $9.8 million, with non-cash items contributing to the difference between net loss and cash used in operating activities[225]. - Other income increased to $9.04 million for Q2 2024, compared to $1.75 million in Q2 2023, primarily due to a $9.3 million gain from the fair value of liability classified Merger Warrants[210]. - For the six months ended June 30, 2024, other expense netted $3.7 million, a change of $8 million from $4.4 million income in the same period in 2023, largely due to a $7 million loss in fair value of Legacy Serina Convertible Notes[211]. Research and Development Expenses - Research and development expenses for Q2 2024 were $1.6 million, a 232.8% increase from $0.5 million in Q2 2023[203]. - For the first half of 2024, research and development expenses totaled $2.7 million, up 207.5% from $0.9 million in the same period of 2023[204]. - The increase in research and development expenses was primarily due to a non-recurring $0.3 million severance expense and increases in salaries and consulting services[205]. - The company expects research and development expenses to increase substantially as it continues to invest in product candidate development and clinical trials[194]. - The company anticipates that research and development expenses will continue to increase as it seeks to advance its product candidates[220]. General and Administrative Expenses - General and administrative expenses for Q2 2024 reached $2.3 million, a 391.1% increase compared to $0.5 million in Q2 2023[203]. - In the first half of 2024, general and administrative expenses were $3.5 million, reflecting a 232.4% increase from $1.1 million in the same period of 2023[204]. - General and administrative expenses increased mainly due to $0.6 million in professional legal and accounting services related to a merger completed on March 26, 2024[208]. - The company anticipates that general and administrative expenses will rise over the next several years to support ongoing research and development and compliance as a public company[200]. Cash Flow and Financing - As of June 30, 2024, the company had $6.1 million in cash and cash equivalents, with $2.9 million drawn from the 2022 Secured Note and $4.99 million received from Juvenescence through Post-Merger Warrants[215]. - The net cash used in operating activities for the six months ended June 30, 2024, was $9.6 million, a significant increase of 509.4% from $1.57 million in the same period in 2023[224]. - Net cash provided by financing activities for the six months ended June 30, 2024, was $8.1 million, primarily from the exercise of Post-Merger Warrants and credit facilities[227]. - The company expects to incur substantial expenditures for product development and will require additional financing to continue operations beyond 2025[221]. Internal Controls and Compliance - The company identified material weaknesses in internal controls over financial reporting, including insufficient qualified accounting staff and reliance on manual reporting processes[232]. - A remediation plan has been initiated to address these weaknesses, involving the engagement of financial operations consultants and the appointment of a new Controller for Legacy Serina[235]. - The company believes that its quarterly report fairly presents its financial condition and results of operations, despite the identified weaknesses[230]. - There were no changes in internal control over financial reporting that materially affected its effectiveness during the reporting period[237]. - The company is committed to ongoing monitoring and enhancement of internal controls as necessary, but acknowledges inherent limitations in their effectiveness[237]. - The material weaknesses will not be remediated until the remediation plan is fully developed and tested for effectiveness[236]. - The company has implemented direct management oversight and the use of legal and accounting professionals to mitigate identified weaknesses[233]. - The company is focused on ensuring the reliability of its financial reporting processes moving forward[230]. Legal Matters - A putative shareholder class action lawsuit was filed against the company related to the Merger Agreement, but was dismissed on March 5, 2024[240]. - The company continues to face potential litigation matters that could materially affect future results of operations and financial position[239].

[Business Highlights](index=1&type=section&id=Recent%20Highlights) In Q1 2024, Serina Therapeutics advanced its lead drug candidate SER-252 for Parkinson's Disease, with plans for a Phase 1 trial in 2025. The company completed a merger with AgeX Therapeutics, resulting in a new NYSE American listing under the ticker "SER". Additionally, Dr. Simba Gill was appointed as Executive Chairman to guide strategic growth - The company is advancing its lead drug candidate, **SER-252** (POZ-apomorphine), for advanced Parkinson's Disease and anticipates submitting an IND application to the FDA to start a Phase 1 clinical trial in **2025**[1](index=1&type=chunk) - Completed a merger with AgeX Therapeutics and began trading on the NYSE American market under the ticker "**SER**" on March 27, 2024[2](index=2&type=chunk) - Appointed Dr. Simba Gill as Executive Chairman to leverage his biotech and pharma experience to guide the company's growth and strategic expansion[3](index=3&type=chunk) [Liquidity and Capital Resources](index=1&type=section&id=Liquidity%20and%20Capital%20Resources) Serina increased its secured line of credit from Juvenescence Limited by a total of $2.925 million across March and May 2024, extending the repayment date to December 31, 2024. As of March 31, 2024, the company held $8.8 million in cash, cash equivalents, and restricted cash, while owing $10.4 million in principal and fees to Juvenescence - The company's line of credit from Juvenescence Limited was increased by **$2.4 million** on March 26, 2024, and by an additional **$0.525 million** on May 8, 2024[4](index=4&type=chunk) - The repayment date for the Juvenescence line of credit was extended from May 9, 2024, to **December 31, 2024**[4](index=4&type=chunk) Key Liquidity Figures (as of March 31, 2024) | Metric | Amount | | :--- | :--- | | Cash, cash equivalents, and restricted cash | $8.8 million | | Debt to Juvenescence Limited (principal & fees) | $10.4 million | [First Quarter 2024 Operating Results](index=1&type=section&id=First%20Quarter%202024%20Operating%20Results) For Q1 2024, Serina reported a net loss of $9.4 million, a stark contrast to the $1.7 million net income in Q1 2023. This was driven by operating expenses more than doubling to $2.3 million, due to increased R&D and merger-related G&A costs. A significant $7 million non-cash expense from the change in fair value of convertible promissory notes also heavily impacted the bottom line Q1 2024 vs Q1 2023 Financial Performance (amounts in thousands or millions as specified, except per share data) | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Grant Revenues | $5,000 | $30,000 | | Operating Expenses | $2.3 million | $1.0 million | | Net Income (Loss) | ($9.4 million) | $1.7 million | | EPS (Basic & Diluted) | ($3.38) | $0.77 (Basic), $0.20 (Diluted) | - Research and development expenses increased by **$0.7 million** to **$1.1 million**, while general and administrative expenses rose by **$0.6 million** to **$1.2 million**, largely due to professional services for the merger[8](index=8&type=chunk)[9](index=9&type=chunk) - Net loss was primarily impacted by a **$7.0 million** charge related to the change in fair value of convertible promissory notes, which were converted to common stock on March 26, 2024[10](index=10&type=chunk) [Going Concern Considerations](index=2&type=section&id=Going%20Concern%20Considerations) The company's management has determined that its current cash reserves and recent borrowings are insufficient to fund operations for the next twelve months. This situation raises substantial doubt about Serina's ability to continue as a going concern - Based on projected cash flows, the company believes its cash, cash equivalents, and recent borrowings are not sufficient to satisfy anticipated operating requirements for the next **twelve months**[12](index=12&type=chunk) - These factors raise **substantial doubt** regarding the ability of the Company to continue as a **going concern**[12](index=12&type=chunk) [Technology and Pipeline](index=2&type=section&id=Technology%20and%20Pipeline) Serina's core technology is the POZ Platform™, which uses a synthetic polymer to enhance drug delivery. Its lead candidate, SER-252, leverages this platform for an apomorphine-based therapy for Parkinson's disease, aiming for continuous stimulation with reduced side effects, with clinical trials planned for 2025. The company also pursues partnerships, including a licensing agreement with Pfizer for LNP drug delivery - The lead candidate, **SER-252**, is an investigational therapy for Parkinson's disease designed to provide continuous dopaminergic stimulation (CDS) and is planned to advance to clinical testing in **2025**[13](index=13&type=chunk) - The proprietary **POZ technology** is engineered to offer greater control in drug loading and precision in release rates for subcutaneously injected drugs, aiming to improve therapies with narrow therapeutic windows[14](index=14&type=chunk) - Serina intends to advance its **POZ platform** through partnerships, highlighted by a non-exclusive license agreement with **Pfizer, Inc.** for use in lipid nanoparticle (LNP) drug delivery formulations[15](index=15&type=chunk) [Financial Statements](index=4&type=section&id=Financial%20Statements) This section provides the company's consolidated financial statements, including balance sheets and statements of operations, reflecting its financial position and performance [Condensed Consolidated Balance Sheets](index=4&type=section&id=SERINA%20THERAPEUTICS%2C%20INC.%20AND%20SUBSIDIARIES%20CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) As of March 31, 2024, Serina's total assets were $10.9 million, while total liabilities stood at $15.2 million, resulting in a stockholders' deficit of $4.3 million. The balance sheet reflects significant changes from year-end 2023, primarily due to the merger and related financing, including a large increase in current liabilities from loans and the conversion of preferred stock Condensed Consolidated Balance Sheets (in thousands) | | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $8,706 | $7,619 | | Total current assets | $8,937 | $7,619 | | **Total Assets** | **$10,856** | **$8,968** | | **Liabilities & Stockholders' Deficit** | | | | Total current liabilities | $14,059 | $1,413 | | **Total Liabilities** | **$15,165** | **$4,858** | | Total stockholders' deficit | ($4,309) | ($32,294) | | **Total Liabilities & Stockholders' Deficit** | **$10,856** | **$8,968** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=SERINA%20THERAPEUTICS%2C%20INC.%20AND%20SUBSIDIARIES%20CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) For the first quarter of 2024, Serina reported a net loss of $9.4 million, or ($3.38) per share. This compares to a net income of $1.7 million, or $0.77 per basic share, for the same period in 2023. The significant loss was driven by a higher loss from operations and a $7.0 million non-cash expense from the change in fair value of convertible promissory notes Condensed Consolidated Statements of Operations (in thousands, except per share data) | | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Total revenues | $5 | $30 | | Loss from operations | ($2,321) | ($962) | | Change in fair value of convertible promissory notes | ($7,017) | $294 | | **Net Income (Loss)** | **($9,437)** | **$1,658** | | **Net Earnings (Loss) Per Share - Basic** | **($3.38)** | **$0.77** | | **Net Earnings (Loss) Per Share - Diluted** | **($3.38)** | **$0.20** |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of exchange on which registered Common Stock, par value $0.0001 per share SER NYSE American FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1436829 (State or other j ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of exchange on which registered Common Stock, par value $0.0001 per share AGE NYSE American FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commissi ...